期刊文献+

载紫杉醇共聚物胶束的合成与表征 被引量:1

Preparation and Characterization of Paclitaxel-loaded Polymeric Micelles
原文传递
导出
摘要 目的:制备一种包封率、载药量高的紫杉醇载体材料。方法:开环聚合法一步合成了两种两亲性共聚物PTL1和PTL2,以核磁和凝胶渗透色谱进行了产物的表征,以固体分散-超声法制备紫杉醇胶束,考察了胶束的载药量、包封率。结果:核磁和凝胶渗透色谱的结果显示得到了目标产物,所制备得到的载紫杉醇胶束包封率可以达到90%以上,载药量为9.5%以上。结论:实验结果表明我们所合成的PTL1和PTL2是好的紫杉醇载体材料。 Objective: To obtain a high loading and encapsulation efficiency micellar cartier of paclitaxel. Methods: Amphiphilic block copolymers PTL1 and PTL2, were synthesized by ring-opening polymerization and their compositon were characterized by 1H-NMR and GPC. Paclitaxel micelles were prepared through solid-dispersion-sonication method. The drug loading and encapsulation efficiency of the micelles were investigated. Results: PTL1 and PTL2 were successfully synthesized The drug loading contents of micelles were higher than 9.5% and the encapsulation efficiency were high than 90%. Conclusion: PTL1 and PTL2 could be promising paclitaxel micellar carders.
出处 《现代生物医学进展》 CAS 2014年第3期441-443,共3页 Progress in Modern Biomedicine
基金 国家自然科学基金项目(81171439/H1816)
关键词 开环聚合 载药量 固体分散一超声法 包封率 Ring-opening polymerization Drug loading Solid dispersion-sonication Encapsulation efficiency
  • 相关文献

参考文献20

  • 1Naill M.C,Kolewe M.E,Roberts S.C. Paclitaxel uptake and transport in taxus cell suspension cultures[J].{H}Biochemical Engineering Journal,2012.50-56.
  • 2Seki M,Ohzora C,Takeda M. Taxol (paclitaxel) production using free and immobilized cells of taxus cuspidata[J].{H}Biotechnology and Bioengineering,1997,(02):214-219.
  • 3Lv P.P,Ma Y.F,Yu R. Targeted delivery of insoluble cargo (paclitaxel) by pegylated chitosan nanoparticles grafted with arg-gly-asp (rgd)[J].{H}Molecular Pharmacology,2012,(06):1736-1747.
  • 4Lv P.P,Wei W,Yue H. Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration[J].{H}Biomacromolecules,2011,(12):4230-4239.
  • 5Friedland D,Gorman G,Treat J. Hypersensitivity reactions from taxol and etoposide[J].{H}JOURNAL OF THE NATIONAL CANCER INSTITUTE,1993,(24):2036.
  • 6Dank M. weekly taxol (paclitaxel) administration in the second-line treatment of breast cancer[J].Magy Onkol,2002,(02):189-191.
  • 7Meerum Terwogt J,van Tellingen O,Nannan Panday V.R. Cremophor el pharmacokinetics in a phase i study of paclitaxel (taxol) and carboplatin in non-small cell lung cancer patients[J].{H}Anti-Cancer Drugs,2000,(09):687-694.
  • 8Hennequin C,Giocanti N,Favaudon V. Interaction of ionizing radiation with paclitaxel (taxol) and docetaxel (taxotere) in hela and sq20b cells[J].{H}CANCER RESEARCH,1996,(08):1842-1850.
  • 9Guchelaar H.J,ten Napel C.H,de Vries E.G. Clinical,toxicological and pharmaceutical aspects of the antineoplastic drug taxol:A review[J].{H}Clinical Oncology(royal College of Radiologists),1994,(01):40-48.
  • 10Wang C,Wang Y,Fan M. Characterization,pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel[J].{H}International Journal of Pharmaceutics,2011,(1-2):251-259.

二级参考文献38

  • 1李晓然,袁晓燕.聚乙二醇-聚乳酸共聚物药物载体[J].化学进展,2007,19(6):973-981. 被引量:15
  • 2谢德明,闫昕.载环孢素纳米球的制备及释放特性[J].中国新药杂志,2007,16(11):869-872. 被引量:1
  • 3Lee WC, Li YC, Chu IM. Amphiphilic poly (D,L-lactic acid)/poly (ethylene glycol)/poly(D,L-lactic acid) nanogels for controlled release of hydrophobic drugs [J]. Macromol Biosci,2006,6(10):846-854.
  • 4Kulkarni RK, Pani KC, Neuman C, et al. Polylactic acid for surgical implants[J].Arch Surg, 1966,93(5):839-843.
  • 5Ignatius AA, Claes LE. In vitro biocompatibility ofbioresorbable polymers: poly(L,DL-lactide) and poly(L-lactide-co-glycolide) [J]. Biomaterials,1996,17(8):831-839.
  • 6Kricheldorf HR, Hachmann-Thiessen H, Schwarz G. Telechelic and star-shaped poly(L-lactide)s by means of bismuth(III) acetate as initiator [J]. Biomacromolecules,2004,5(2):492-496.
  • 7Stefani M, Coudane J, Vert M. In vitro ageing and degradation of PEG-PLA diblock copolymer-based nanoparticies [J]. Polym Degrad Stab,2006,91(l1 ):2554-2559.
  • 8Otsuka H, Nagasaki Y, Kataoka K. Surface characterization of functionalized polylactide through the coating with heterobifunctional poly (ethylene glycol)/polylactide block copolymers [J].Biomacromolecules, 2000,1 (l ):39-48.
  • 9Salem AK, Cannizzaro SM, Davies MC, et al. Synthesis and characterisation of a degradable poly(lactic acid)-poly( ethylene glycol) copolymer with biotinylated end groups [J]. Biomacromolecules,2001,2(2): 575-580.
  • 10Zhang H, Xia H, Wang J, et al. High intensity focused ultrasound-responsive release behavior of PLA-b-PEG copolymer micelles [J]. J Control Release,2009,139(l):31-39.

共引文献8

同被引文献23

  • 1Prasad S, Gupta S C, Tyagi A K, et al. Curcumin, a component of golden spice: firom bedside to bench and back [J]. Bioteehnology ad- vances, 2014, 32(6): 1053-1064.
  • 2Ma J, Fang B, Zeng F, et al. Curcumin inhibits cell growth and inva- sion through up-regulation of miR-7 in pancreatic cancer cells [J]. Toxicology letters, 2014, 231(1): 82-91.
  • 3Zhang K, Rui X, Yan X. Curcumin inhibits the proliferation and inva- siveness of MHCC97-H cells via p38 signaling pathway [J]. Drug de- velopment research, 2014, 75(7): 463-468.
  • 4Yallapu M M, Khan S, Mailer D M, et al. Anti-cancer activity of cur- cumin loaded nanoparticles in prostate cancer[J]. Biomaterials, 2014, 35(30): 8635-8648.
  • 5Singh M, Pandey A, Karikari C A, et al. Cell cycle inhibition and apoptosis induced by curcumin in Ewing sarcoma cell line SK-NEP-1 [J]. Medical oncology (Northwood, London, England), 2010, 27(4): 1096-1101.
  • 6Lin Y G, Kunnumakkara A B, Nair A, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nucle- ar factor-kappaB pathway [J]. Clinical cancer research, 2007, 13(11): 3423-3430.
  • 7Ganta S, Amiji M. Coadministration of Paclitaxel and cureumin in na- noemulsion formulations to overcome multidrug resistance in tumor cells[J]. Mol Pharm, 2009, 6(3): 928-939.
  • 8Misra R, Sahoo S K. Coformulation of doxorubicin and cureumin in poly (D,L-lactide-co-glycolide) nanoparticles suppresses the develop- ment of multidrug resistance in K562 cells[J]. Mol Pharm, 2011, 8(3): 852-866.
  • 9Wang Y J, Pan M H, Cheng A L, et al. Stability of curcumin in buffer solutions and characterization of its degradation products [J]. Journal of pharmaceutical and biomedical analysis, 1997, 15(12): 1867-1876.
  • 10Mackay J A, Chen M, Mcdaniel J R,et al. Chilkoti A. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abol- ish tumours after a single injection [J]. Nature materials, 2009, 8(12): 993-999.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部